Rome, Italy - 28 Aug 2016: Nebivolol prevents anthracycline-induced cardiotoxicity, according to research presented at ESC Congress 2016 today by Professor Mirela Cleopatra Tomescu, a cardiologist at Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.1
"Breast cancer is a major public health problem worldwide, with a death rate of about 1 in 33 patients," said Professor Tomescu. "Anthracyclines are a class of powerful pharmacological agents widely used in the treatment of breast cancer but they have a toxic effect on the heart, inducing heart failure."